吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察
Clinical observation of gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer
黄芳 1鲁敏2
作者信息
- 1. 同济大学附属上海市肺科医院 胸外科,上海 200433
- 2. 同济大学附属上海市肺科医院 护理部,上海 200433
- 折叠
摘要
目的 研究分析吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察.方法 选取我院2014年1月～2015年9月收治的50例晚期非小细胞肺癌患者为研究对象,随机分为对照组和实验组,每组患者各为25例.对照组患者进行特罗凯治疗,实验组患者进行吉西他滨治疗.比较分析实验组与对照组患者的相关临床指标.结果 经过对应的治疗后,实验组25例患者中,12例患者完全缓解,8例患者部分缓解,3例患者稳定,2例患者进展,治疗有效率为75.0%,临床获益率92.0%.对照组患者中,4例患者完全缓解,2例患者部分缓解,9例患者稳定,10例患者进展,治疗有效率为24.0%,临床获益率为60.0%.可得,实验组患者治疗有效率与临床获益率显著高于对照组,差异具有统计学意义(P＜0.05).1年后,实验组患者的生存率例数为22例,生存率为88.0%,对照组患者生存例数为14例.可得,实验组患者的生存率显著高于对照组,差异具有统计学意义(P＜0.05).对照组不良反应发生率显著高于对照组,差异具有统计学意义(P＜0.05).结论 吉西他滨单药治疗老年晚期非小细胞肺癌能够在很大程度上提高治疗效果,安全性较好,不良反应发生率低,患者生存率高,具有临床进一步推广和应用的意义.
Abstract
Objective To investigate the clinical efficacy of gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.Methods 50 patients in our hospital from January 2014 to September 2015 were selected as the research object, and were randomly divided into the control group and the experimental group, each group of 25 patients each.The patients in the control group were treated with special therapy, and the patients in the experimental group were treated with gemcitabine.The clinical indexes of the experimental group and the control group were compared and analyzed.Results After the treatment, the experimental group of 25 patients, 12 cases of patients with complete remission, 8 cases partial remission, 3 cases were stable, 2 patients progressed, the effective rate was 75%, clinical benefit rate of 92%.In the control group, 4 patients had complete remission, 2 patients had partial remission, 9 patients were stable, 10 patients progressed, the treatment efficiency was 24%, and the clinical benefit rate was 60%.The effective rate and the clinical benefit rate of the experimental group were significantly higher than that of the control group (P<0.05).1 years later, the survival rate of patients in the experimental group was 22, the survival rate was 88%, and the number of patients in the control group was 14.The survival rate of the experimental group was significantly higher than that of the control group, with statistical difference (P<0.05).Conclusion Gemcitabine monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer can improve the therapeutic effect to a great extent, good safety, low incidence of adverse reactions, high survival rate, with further clinical promotion and application significance.
关键词
吉西他滨/单药治疗/老年晚期非小细胞肺癌/临床效果Key words
gemcitabine/monotherapy/elderly advanced non-small cell lung cancer/clinical outcome引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据